Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study
Authors' conclusion
In adults with T1D and overweight or obesity, adjunctive tirzepatide treatment was associated with clinically meaningful reductions in percentage body weight and insulin requirements.
Study context
- Population
- Adults with T1D, BMI ≥ 27 kg/m², continuous glucose monitoring (CGM) use and baseline and follow-up electronic medical record data, Royal North Shore Hospital and Northern Sydney Endocrine Centre, 2020–2025matched cohort
- Participants
- 23 vs 23
- Exposure
- Tirzepatide vs control
- Tirzepatiden = 23
- Controln = 23reference
- Outcome
- Changes in percentage change in body weight, HbA1c, total daily insulin dose and CGM-derived metrics from baseline to follow-up
- Follow-up
- Baseline to
Methodological detailsmatched cohort, propensity score-matched
- Matched cohort
- Propensity score-matched
Main finding
As reported in the abstract
Body weight change · mean follow-up 28 (tirzepatide) and 31 (control) weeks
Tirzepatide
−10.01%
mean · SD 4.74%
Control
+0.69%
mean · SD 3.77%
Adj-p < 0.0001
Observational data: associations, not effects.
Further findings
Mean, U/day
| Outcome | Tirzepatide | Control | P value |
|---|---|---|---|
| Total daily insulin dose change | −21.82 (SD 16.30) | +5.62 (SD 11.63) | adj-p = 0.002 |
GMI, glucose SD and daily carbohydrate intake · baseline to end-of-study
- Tirzepatide associated with a reduction in GMI, glucose SD and daily carbohydrate intake
Other CGM, blood pressure, lipid, hepatic and renal outcomes
- Did not differ
Tirzepatide dose
- Most common dose 5 mg/week
- 52.2% participants
Original publication
Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study. Diabetes Obes Metab. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →